Checkpoint Therapeutics (NASDAQ:CKPT) Stock Price Expected to Rise, Lake Street Capital Analyst Says

Checkpoint Therapeutics (NASDAQ:CKPT) had its price objective hoisted by Lake Street Capital from $4.00 to $7.00 in a research note released on Monday morning,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ CKPT opened at $3.39 on Monday. Checkpoint Therapeutics has a one year low of $1.36 and a one year high of $4.50. The firm has a market capitalization of $165.53 million, a P/E ratio of -1.84 and a beta of 1.34. The company’s fifty day moving average is $3.50 and its two-hundred day moving average is $2.67.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, sell-side analysts forecast that Checkpoint Therapeutics will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Magnus Financial Group LLC raised its holdings in Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 4,000 shares during the last quarter. Choreo LLC grew its position in shares of Checkpoint Therapeutics by 12.2% in the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares during the period. PVG Asset Management Corp lifted its position in Checkpoint Therapeutics by 9.2% during the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock worth $336,000 after buying an additional 12,676 shares during the period. Virtu Financial LLC purchased a new stake in Checkpoint Therapeutics in the 3rd quarter valued at about $30,000. Finally, XTX Topco Ltd acquired a new position in shares of Checkpoint Therapeutics during the 2nd quarter valued at about $34,000. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.